Other · developed by Immunocore
IMC-I109V is an investigational agent studied in chronic hepatitis B, given as single and multiple doses.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05867056 | Phase 1 | Hepatitis B, Chronic | Withdrawn | IMCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatitis B, Chronic
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMCR page.
See IMCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMCR catalysts and pipeline →